Back to News
Market Impact: 0.2
Vaxart Q3 Earnings Call Highlights
Source: marketbeat.com
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Vaxart expects to report efficacy and safety data from the main cohort of its Phase 2b COVID-19 vaccine trial by mid-2027. Executives said during a third-quarter stockholder fireside chat that the company’s current cash runway extends into Q2 2027.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.05
More News
- China AI bust threatens Xi’s ’Wall Street East’ ambitions
- Berkshire Hathaway speeds up stock buybacks, though profit falls
- Cabaletta Bio reports phase 1/2 data for autoimmune therapy
- Nvidia CEO Jensen Huang faces bipartisan congressional scrutiny over reported China spy link
- Apple Explores Turning Siri AI Into ChatGPT Dots-Like Agent; iOS 28 Shake-Up
- How sustainable is the AI investment boom after Thursday’s selloff?